Comparison of common mutation profiles in tumors, plasma EVs and ctDNA confirmed the high sensitivity of plasma EV testing, which allowed for the detection of BRAF, KRAS, and EGFR mutations present in NSCLC patient tumors (n = 43) in 95% of plasma EV nucleic acid samples [107]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.